Wall Street set for higher open as oil rebounds
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- Wall Street ends lower, off record highs, as Treasury yields climb
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Chip stock could soar nearly 200%, analyst says: "If you don’t buy it, they will"
- Musk rules out TSMC role in Terafab operations; Intel gains
- HubSpot to cut 7% of workforce in restructuring plan
- Anthropic launches Claude Haiku 5.5 with tiered pricing structure
- Caribou Biosciences to halt CAR-T programs, explore sale
- Sportradar to sell Synergy Sports coaching unit for $170M
- Emera and Canadian Utilities agree to merge in $72B all-share deal
Allergan (AGN) Ratings Affirmed by Moody's Amid Scrubbed Deal with Pfizer
April 6, 2016 4:51 PM EDTMoody's Investors Service confirmed the Baa3 senior unsecured rating of subsidiaries of Allergan plc (NYSE: AGN), including Actavis, Inc., Actavis Funding SCS, Allergan Inc., and Forest Laboratories, Inc. (together, "Allergan"). The confirmation follows the announcement of the termination of the proposed combination with Pfizer Inc. (rated A1 stable). The outlook is stable.
"Allergan will likely pursue acquisitions and share repurchases that will erode its significant cash balance following the divestiture of the generics business to Teva" said Jessica Gladstone, Senior Vice President with Moody's. "However, we believe this will be balanced with enough... More
BMO Capital Reiterates Outperform on Pfizer (PFE) Following Allergan Merger Termination
April 6, 2016 10:42 AM EDTBMO Capital reiterated an Outperform rating and $39.00 price target on Pfizer (NYSE: PFE) following the company's announcement the merger agreement with Allergan plc was terminated. BMO believes that Pfizer will likely look for more deals to strengthen its innovative business, and the recent weakness... More



